| | TMZ 62,5 μM | TMZ 250 μM | TMZ 500 μM | TMZ 1000 μM |
|---|
TG1 P35
| 95 ± 7 | 94 ± 4 | 95 ± 5 | 67 ± 4 |
TG1 P70
| 95 ± 5 | 87 ± 5 | 83 ± 4 | 66 ± 6 |
TG1 P90
| 96 ± 5 | 87 ± 5 | 78 ± 7 | 58 ± 7 |
TG10
| 98 ± 6 | 97 ± 5 | 80 ± 6 | 59 ± 4 |
TG16
| 90 ± 5 | 80 ± 7 | 75 ± 5 | 62 ± 6 |
TG16 CD133+
| 92 ± 5 | 81 ± 7 | 74 ± 5 | 67 ± 8 |
TG16 CD133-
| 91 ± 6 | 75 ± 6 | 71 ± 5 | 60 ± 6 |
TG1 without GF
| 92 ± 6 | 85 ± 6 | 78 ± 6 | 62 ± 7 |
TG1 10% SVF
| 90 ± 5 | 80 ± 5 | 82 ± 6 | 79 ± 5 |
- Cells cultured from tumors TG1, TG10 and TG16 were exposed for 48h to different concentrations of temozolomide (TMZ). The analysis was performed on three passages of TG1 (weeks 35, 70 and 90 after clonal selection), and on TG10 and TG16 at passage 40. It was additionally performed on cultures of TG16 initiated from CD133+ (TG16 CD133+) or CD133- (TG16 CD133-) sphere-forming cells. The influence of growth factors (GF) or serum (10%SVF) on the cells response to temozolomide was evaluated using cells cultured for 10 days without FGF/EGF or for 7 days in the presence of 10% fetal calf serum, prior temozolomide addition. Cell viability was determined using WST1 test. Results are presented as % of control. Mean ± sem of three independent experiments, each experiment performed in triplicates.
